Riskpilot← Back to searchSign inGet full accessStrominnate Therapeutics AB
ABActiveOrg 5593567125Dialoggränden 9 EResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20211-4 employees
Revenue 2024
SEK 0
EBITDA margin
—
+36% vs 2023
Equity ratio
85.5%
Financial strength
Net profit 2024
SEK -491K
+36% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -493K | +36% |
| Net profit | SEK -491K | +36% |
| Total assets | SEK 2M | -36% |
| Equity | SEK 1,7M | -23% |
| Employees | — | — |
Legal name
Strominnate Therapeutics AB
Org number
5593567125
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23 december 2021
Share capital
SEK 28 917
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning och utveckling, tillverkning och idka handel med cell-, medicinska-, farmaceutiska- och kemitekniska produkter, förvärva, upplåta och överlåta immateriella rättigheter för sådana produkter samt därmed förenlig verksamhet.
Address
Dialoggränden 9 E
Email
tania.ramos@strominnate.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 36 | 0 |
| Staff expenses | — | — | −361 |
| EBITDA | −197 | −767 | −493 |
| Depreciation & amort. | −0 | −0 | — |
| EBIT | −197 | −767 | −493 |
| Net financials | — | — | 2 |
| Profit before tax | −197 | −767 | −491 |
| Tax | −0 | −0 | — |
| Net profit | −197 | −767 | −491 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 609 | 3 056 | 1 967 |
| Equity | 481 | 2 173 | 1 682 |
| Long-term debt | 0 | 0 | — |
| Short-term debt | 128 | 883 | 285 |
| Total debt | 128 | 883 | 285 |
EBITDA margin
-49316000.0%
This company
15.8%
Market median
-312126682% vs market
20222024
Equity ratio
85.5%
This company
38.2%
Market median
+124% vs market
20222024
Return on equity
-29.2%
This company
18.4%
Market median
-259% vs market
20222024
Net profit margin
-49105800.0%
This company
8.1%
Market median
-606244544% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MS Chief Auditor | Chief Auditor | 2022 |
TR Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2026 | |
| Chairman | 2026 | |
| Former (5) | ||
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2022 – 2023 | |
| Chairman | 2022 – 2026 | |
| Chairman | 2022 – 2025 | |
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Strominnate Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Tania Ramos Moreno | Chief Executive Officer | 0 companies |
| Julio Alberto Enriquez Perez | Board of Directors | 0 companies |
| Karin Marie Christine Widstrand | Deputy Board Member | 0 companies |
| Nai-Soon Anna Löfgren | Board of Directors | 0 companies |
| Hanna Cecilia Jädert Widblom | Board of Directors | 0 companies |
| Eddie Eggert Thordarson | Chairman | 0 companies |
| Margaret Ann Bywater-Ekegärd | Board of Directors | 0 companies |
| Lars Olof Hedbys | Chairman | 0 companies |
| Christopher Andrew Bravery | Chairman | 0 companies |
| Mathias Lars Ove Lidgren | Board of Directors | 0 companies |